Track topics on Twitter Track topics that are important to you
Includes approximately 5,800,000 shares of Cerecor common stock at closing, and development milestones worth up to $15M
Cerecor's substrate replacement therapy CERC-801, being developed to treat patients with inborn error of metabolism, was give -More-
Transaction worth approximately $26.6 Million in Stock Plus Potential Milestones Accelerates Cerecor’s Transformation Strategy; Strengthens Rare Disease Pipeline and Expands Pediatric Portfolio B...
BALTIMORE, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on the near-term goal of becoming a leader in the U.S. pediatric market space, today a...
BALTIMORE, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (“Cerecor” or the “Company”) (NASDAQ: CERC), a fully integrated biopharmaceutical company with commercial operations and research a...
New Leadership Supports Company Evolution into Innovative Specialty Pharmaceutical Company BALTIMORE, July 16, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), today announced executive manag...
BALTIMORE, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on the near-term goal of becoming a leader in the U.S. pediatric market space, today an...
Driven by an innovative team of industry experts and leading scientists, Cerecor aspires to develop neuroscience drugs that will make a difference. We are committed to improving t...
We have published hundreds of Cerecor Inc. news stories on BioPortfolio along with dozens of Cerecor Inc. Clinical Trials and PubMed Articles about Cerecor Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cerecor Inc. Companies in our database. You can also find out about relevant Cerecor Inc. Drugs and Medications on this site too.